Advanced Health Intelligence Ltd Announces Implementation of ADS Ratio Change
NEW YORK, June 29, 2023 (GLOBE NEWSWIRE) -- Advanced Health Intelligence Ltd (ASX/NASDAQ:AHI) (“Advanced Health Intelligence”, “AHI” or the “Company”)...
COVID-19
Zenocutuzumab (Zeno) granted Breakthrough Therapy Designation by the U.S. Food & Drug Administration for the treatment of NRG1+ pancreatic cancer
UTRECHT, The Netherlands and CAMBRIDGE, Mass., June 29, 2023 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company...
Vir Biotechnology Appoints Sasha Damouni Ellis as Executive Vice President and Chief Corporate Affairs Officer
SAN FRANCISCO, June 29, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the appointment of Sasha Damouni...
Aquestive Therapeutics Provides Business Update and Announces Chief Medical Officer Appointment
Submitted NDA for Libervant™ (diazepam) Buccal Film for treatment of seizure clusters in patients between two and five years of...
BioSig Joins Webull Corporate Connect
Webull’s investor community can now access real-time BioSig investor communications and Q&AWestport, CT, June 29, 2023 (GLOBE NEWSWIRE) -- BioSig...
NeuBase Presents Non-Human Primate Data Illustrating Stealth Editors™ are Non-Immunogenic, Opening the Door to Redosing
New preclinical data validates that Stealth Editors™ are non-immunogenic, as featured in a poster presentation at the 28th American Peptide...
Microbot Medical Successfully Completes an Extensive Pre-Clinical Study Performed in the US
The study was conducted over two days by a team of global key opinion leaders and with participation of executives...
Urica Therapeutics Announces Topline Data from the Phase 1 Clinical Trial Evaluating Dotinurad in Healthy Volunteers in the United States
Data from Phase 1 clinical trial in healthy volunteers show comparable pharmacokinetic, pharmacodynamic and safety profile between U.S. and Japanese...
Emergex Appoints Sir Michael Rake as Board Chairman
Highly experienced international Board Leader joins Emergex as the company grows and progresses clinical development of its pipeline of T...
XORTX Announces Results of Annual and Special Meeting of Shareholders
CALGARY, Alberta, June 29, 2023 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX...
TScan Therapeutics Announces Transition of Chief Financial Officer
WALTHAM, Mass., June 29, 2023 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the...
New research finds Imprivata digital identity solutions accelerated emergency COVID-19 vaccine delivery for Northern Ireland Public Health Service
The company’s single sign-on and identity governance solutions helped Health and Social Care (HSC) Trust onboard 500 personnel in under...
Mainz Biomed Secures up to $50M in New Funding
Provides option to access capital to support commercial and clinical programsBERKELEY, Calif. and MAINZ, Germany, June 29, 2023 (GLOBE NEWSWIRE)...
Junshi Biosciences Announces Initiation of Phase 3 Study of Tifcemalimab plus Toripalimab for Treatment of Limited-stage Small Cell Lung Cancer
SHANGHAI, China, June 29, 2023 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a...
Alvotech Provides Regulatory Update on Second Biologics License Application for AVT02
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today...
Alvotech Provides Regulatory Update on Second Biologics License Application for AVT02
REYKJAVIK, Iceland, June 28, 2023 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture...
Sirona Biochem Advances Antiviral Research with New Compound Candidates for Testing at the ICGEB
VANCOUVER, British Columbia, June 28, 2023 (GLOBE NEWSWIRE) -- June 28, 2023 – Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB)...
Eloxx Pharmaceuticals Key Opinion Leader Event Highlights Significant Unmet Need in Treatment of Alport Syndrome Patients with Nonsense Mutations and Additional Positive Results from Phase 2 Clinical Study Evaluating ELX-02
Alport syndrome is a rare progressive hereditary glomerular kidney disease caused by variants in COL4A and patients have significant unmet...
Ambrx Announces Closing of $75 Million Market Priced Registered Offering
SAN DIEGO, June 28, 2023 (GLOBE NEWSWIRE) -- Ambrx Biopharma Inc., or Ambrx (or the “Company”) (NASDAQ: AMAM), today announced...
Biora Therapeutics Announces New Patents for its NaviCap™ Targeted Oral Delivery Platform
SAN DIEGO, June 28, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic...